A Systemic Review on Clinical Trials of 2-Deoxyglucose in Treating Covid-19

Aafrin Sheikh*, Vaishnavi Padole, Sachin More, Sachin Mendhi
Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra, India.
*Corresponding author’s E-mail: 2102aafrin sheikh@gmail.com

Received: 10-07-2021; Revised: 22-09-2021; Accepted: 30-09-2021; Published on: 15-10-2021.

ABSTRACT

After sudden outbreak of covid-19 pandemic, to overcome this chaotic situation many drug therapies have been used which includes Chloroquine, Hydroxychloroquine (Antimalarial), Lopinavir and Ritonavir (antiviral), Nafamostat (Sririn protease inhibitor), Famotidine (Antihistamines), Nitazoxanide (Anti-infective), Evermectin (Anti-parasitic), Corticosteroids, Tocilizumab & Sarilumab (Inflammatory cytokine), Fluvoxamine(Anti-depressants), but due to prominent effect of 2-DG it has been extensively used against SARS-CoV-2. It is a glucose molecule which was approved for the emergency treatment in covid-19 pandemic against SARS-CoV-2 by inhibiting glycolysis. The energetic cycle. It shows more highlighting effect with combinational approach. This drug was sanctioned by Drug Controller General of India (DCGI) and has been developed by Institute of medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organization (DRDO), together with Dr Reddy’s Laboratories (DRL), Hyderabad.

Keywords: Clinical trials, covid-19, 2-Deoxyglucose, antiviral.

INTRODUCTION

Clinical trials are widely considered the simplest source of evidence on the efficacy and safety of medical interventions. Clinical test may be a systemic investigation in human subjects for evaluating the security and efficacy of any new drug. Trials of first in school drugs also provide the foremost rigorous test of causal mechanisms in human disease. Findings of clinical trials inform regulatory approvals of novel drugs, key clinical practice decisions, and guidelines and fuel the progress of translational medicine. However, this model relies unproved activity being top quality, transparent, and discoverable.

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be a pandemic disease and is that the major explanation for deaths worldwide. The clinical complexities (inflammation, cytokine storm, and multi-organ dysfunction) related to COVID-19 poses constraints to effective management of critically ill COVID-19 patients. Low dose radiotherapy (LDRT) has been evaluated as a possible therapeutic modality for COVID-19 pneumonia. However, thanks to heterogeneity in disease manifestation and inter-individual variations, effective planning for LDRT is restricted for this large-scale event. 2-deoxy-D-glucose (2-DG) has emerged as a polypharmacological agent for COVID-19 treatment thanks to its effects on the glycolytic pathway, anti-inflammatory action, and interaction with viral proteins. They propose that 2-DG are going to be a possible adjuvant to reinforce the efficacy of LDRT within the treatment of COVID-19 pneumonia.1

2-deoxy glucose used in emergency situation was approved by Drugs Controller General of India (DCGI) for the treatment of covid patients. The drug has been developed by Institute of medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), together with Dr Reddy’s Laboratories (DRL), Hyderabad.

2-DG may be a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, in order that it cannot undergo further glycolysis. As such, it acts to competitively inhibit the assembly of glucose-6-phosphate from glucose at the phosphoglucoisomerase level which is a crucial step of glycolysis.1,2

Clinical trials are the set of tests during a medical research and drug development that generate safety and efficacy data for health interventions in citizenry. These are conducted only when:

1) Satisfactory information has been gathered on the standard of the nonclinical safety.
2) Health authority/ethics committee approval is granted within the country where approval of the drug is sought.
3) Clinical trials are conducted consistent with an idea, called a protocol which describes:
4) The sorts of patients who may enter the study
5) The schedules of tests and procedures
6) The drugs involved
7) The dosages, or amount of the drug
8) The length of the study
9) What the researchers hope to find out from the study.²

Eligibility criteria for clinical trials
All clinical trials have guidelines, called eligibility criteria, about who can participate. The standards are supported by such factors as age, sex, type and stage of disease, previous treatment history, and other medical conditions. This helps to scale back the variation within the study and to make sure that the researchers are going to be ready to answer the questions they decide to study. Therefore, not everyone who applies for a clinical test are going to be accepted.³

It is important to check drugs and medical products within the people they’re meant to assist also important to conduct research during a sort of people, because different people may respond differently to treatments.¹,²

Phases of Clinical Trials
Clinical trials follow a specific timeline, from early, small-scale, phase 1 studies to late-stage, large-scale, phase 3 studies. While there are many steps involved within the development of latest drugs, clinical trials, which structure clinical research, are part of drug development that involves people. The key goals and knowledge about the varied clinical research phases are as follows:

Phase 0 Study/Microdosing
- It is the study of new drug in micro doses to derive PK information in humans before undertaking phase 1 studies is called phase 0. It has less chance of adverse effects as well as have short duration.
- Micro dose: Less than 1/100 of the dose of a test substance calculated to produce pharmacological effect with maximum dose <100 micrograms. These are very early studies of the pharmacodynamics and pharmacokinetic properties of a potential drug in humans. These approaches accelerate the drug development without compromising clinical safety.

Preclinical Studies
- Before a clinical trial begins, researchers perform extensive preclinical studies in the lab to make sure that their methods (e.g., drug, procedure, preventative measure, or diagnostic) are not harmful.
to people. The level of harm is measured in terms of toxicity. The research in preclinical trials is not performed on people. Instead, potential drugs and therapies, and the methods to administer them, are first tested in cells or animals, or both, long before they make it to human trials.

- Usually, preclinical studies are not very large. However, these studies provide detailed information on dosing levels and are required before clinical trials can begin after preclinical testing, researchers review their findings and decide whether the method should be tested in people. If the treatment appears safe in cells or animals, it proceeds to phase 1, where the potential medical treatment is first tested in humans. 

- Major areas are: Pharmacodynamics studies in vivo in animals, in vitro preparation. Pharmacokinetics i.e. absorption, distribution, elimination studies. Acute, sub-acute, chronic toxicity studies. Therapeutic index (safety and efficacy evaluation).

**Phase I Study**

- The aim of phase 1 trial is to determine the maximum tolerated dose (MTD) of the new treatment. MTD is found by escalating the treatment dose until the dose limiting toxicity is reached. Once the preclinical studies have shown that a clinical method may work and appears safe, it is tested on a very small group of healthy volunteers for a few hours or days, up to a few months or even to a year or two. If the clinical trials are investigating cancer or rare diseases, the phase 1 trials may enrol these patients rather than healthy volunteers.

- In the case of potential medical treatments or drugs, a phase 1 study determines safety for humans in a few different ways including side effects, how the body absorbs, distributes, and eliminates the drug, and whether it is safe to use in combination with other medications.

- At the end of phase 1, if the study treatment and method of administration appear safe in healthy people, the next phase of development is phase 2 where it is tested on a slightly larger number of people with the targeted disease. According to the FDA, an estimated 70% of drugs move from phase 1 to phase 2.

Kinds of phase 1 are

1. Single ascending dose studies (SAD): Small groups (3) of subjects are given and tested for a period of time.

2. Multiple ascending dose studies (MAD): A group of patients receives multiple small doses of drug.


**Pre-requisites**

1) Pre-clinical data
2) IND application
3) Approval by the regulatory authority
4) Protocol approved by the Ethics community
5) Adherence to Declaration of Helsinki/ICH-GCP guidelines, at the start as well as from time to time, during the study.

**Phase II Study**

- Phase 2 clinical trials build on the results of phase 1 by testing the method on participants with the health condition targeted in the study. Trials can also be blinded, meaning that the participants do not know what study treatment they are receiving to ensure effectiveness and impartiality of the study treatment. Some trials are placebo-controlled, meaning that some participants will get a placebo or “sugar-pill” and not the medication or study treatment under investigation. Other trials are active-controlled, meaning that some participants will get a study treatment that is already available for the targeted health condition.

- It is carried out to confirm effectiveness, monitor side effects, evaluate study i.e. Efficacy in patients (Primary objective) and Safety issues (Secondary objective). Duration: 6 months to several years.

Types of phase 2 clinical trials are

**Table 1**: Types of phase 2 clinical trials

<table>
<thead>
<tr>
<th>Phase II a</th>
<th>Phase II b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early phase</td>
<td>Late phase</td>
</tr>
<tr>
<td>Pilot clinical trials</td>
<td>Pivotal clinical trials</td>
</tr>
<tr>
<td>20-200 patients</td>
<td>50-300 patients</td>
</tr>
<tr>
<td>Not multicentre</td>
<td>Multicentre</td>
</tr>
<tr>
<td>Single blind comparison with a standard drug</td>
<td>Double blind compared with a placebo or standard drug</td>
</tr>
</tbody>
</table>

**Pre-requisites**

1) Review of phase 1 data- Innovator, IRB, DCGI
2) Prior approval by IRB and DCGI
3) For new action of marketed drug, start with phase II (phase 1 exemption obtained).

**Phase III Study**

- Phase 3 clinical trials are designed to test whether the investigative treatment is better than the standard clinical method for the targeted health condition. This is therapeutic confirmatory trials.

- Phase 3 studies are tested over a longer period than phase 1 or phase 2 studies and include many more participants with the targeted disease, often between 300 to 3,000. By testing more participants, researchers can more confidently see if the investigational treatment has any adverse effects. If phase 3 is completed successfully, as are approximately 25%-30% of such studies, the new method or study treatment can be submitted to the regulatory agency for approval and eventual use by the general population. Once approved, the new medication can then be marketed in the United States.

- It determines optimal dosage schedules for use in general and to assess overall and relative therapeutic value of the new drug efficacy, safety and special properties. These are large scale, randomised, multicentric, controlled trials with target population several 100’s to 3000’s patients and takes up to 5 years.

**Subtypes of phase III studies are**

<table>
<thead>
<tr>
<th>Table 2: Types of phase III studies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phase III a</strong></td>
</tr>
<tr>
<td>Prior to NDA</td>
</tr>
<tr>
<td>Generate data on safety and efficacy.</td>
</tr>
</tbody>
</table>

**Pre-requisites**

1) Efficacy and dose schedule defined in phase II studies.
2) No gross ADR’s.
3) Marketing inputs favourable.
4) Long term preclinical safety studies completed i.e. chronic toxicity, reproductive toxicity, carcinogenicity.
5) IRB and DCGI approval obtained.

- These is end of clinical trial activities which are sponsored by:

**Phase IV Study**

- Phase 4 are known as post marketing surveillance (PMS). These are clinical trials which collect results after a medication has been introduced into the general population to see how well it works on “real life patients” in order to determine the long-term benefits and risks.

- Phase 4 studies are observational studies that collect data from real-life patients who are taking a medication as prescribed by their doctors. Phase 4 clinical studies are usually performed by the pharmaceutical or biotechnology companies that manufacture the study treatment. It helps to detect rare ADR’s and drug interactions. Harmful effects discovered may result in a drug being no longer sold or restricted to certain uses.

- It helps to detect rare ADR’s and drug interactions. Harmful effects discovered may result in a drug being no longer sold or restricted to certain uses.

- On September 30, 2004. Merck withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. It confirms the efficacy and safety profile in large populations during practice and detect the unknown adverse effects.

**Reporting of ADR**

If health care personal suspects that a particular medication is associated with an adverse event observed during the course of caring for a patient, he can report the ADR to a formal reporting system.

**Various reporting systems are:**

- WHO international system
- USFDA- Medwatch
- UK- Yellow card system
- INDIA- National pharmacovigilance programme (CDSCO)
Now, to understand mechanism of 2-deoxyglucose in covid-19, the pathophysiology of the virus should be known—

Structure And Pathophysiology of Covid-19

Corona viruses are a family of enveloped, non-segmented, single stranded, positive sense RNA viruses classified within the nidovirales order. Corona viruses are a family of enveloped, non-segmented, single stranded, positive sense RNA viruses classified within the nidovirales order.

Coronaviruses contain a non-segmented, positive-sense RNA genome of ~30 kb. The genome contains a 5′ cap structure alongside a 3′ poly (A) tail, allowing it to act as an mRNA for translation of the replicase polyproteins. The replicase gene encoding the non-structural proteins (nsps) occupies two-thirds of the genome, about 20 kb, as against the structural and accessory proteins, which structure only about 10 kb of the viral genome.

The replication cycle of SARS-CoV-2 provide viral mechanism and reveal therapeutic targets. Viral genomic replication is initiated by the synthesis of full-length negative-sense genomic copies, which function as templates for the generation of latest positive-sense genomic RNA. These newly synthesized genomes are used for translation to get more nsps and RTCs or are packaged into new virions.

Stages of the cycle are:
1. Virus entry
2. Translation of viral replication machinery
3. Replication
4. Translation of viral structure protein
5. Virion assembly
6. Release of virus
polyproteins are subsequently cleaved into the individual nsps. Coronavirus encode either two or three proteases that cleave the replicase polyproteins. They are the papain-like proteases (PLpro), encoded within nsp3, and a serine type protease, the most protease, or Mpro, encoded by nsp5. Most coronaviruses encode two PLpros within nsp3, except the γ-coronaviruses, SARS-CoV and MERS-CoV, which only express one PLpro.

Next, many of the nsps assemble into the replicase–transcriptase complex (RTC) to create an environment suitable for RNA synthesis, and ultimately are responsible for RNA replication and transcription of the sub-genomic RNAs.

**Coronavirus receptors are**

<table>
<thead>
<tr>
<th>Virus</th>
<th>Receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha coronaviruses</td>
<td></td>
</tr>
<tr>
<td>HCoV-229E</td>
<td>Aminopeptidase</td>
</tr>
<tr>
<td>HCoV-NL63</td>
<td>Angiotensinogen converting enzyme</td>
</tr>
<tr>
<td>TGEV(transmissible gastroenteritis virus)</td>
<td>Aminopeptidase</td>
</tr>
<tr>
<td>PEDV (Porcine epidemic diarrhoea virus)</td>
<td>Aminopeptidase</td>
</tr>
<tr>
<td>FIPV(Feline infectious peritonitis virus)</td>
<td>Aminopeptidase</td>
</tr>
<tr>
<td>CCoV(Canine coronavirus)</td>
<td>Aminopeptidase</td>
</tr>
<tr>
<td>MHV(Murine hepatitis virus)</td>
<td>Murine carinoembryogenic antigen virus</td>
</tr>
<tr>
<td>SARS-CoV</td>
<td>Angiotensin converting enzyme-2</td>
</tr>
</tbody>
</table>

2-Deoxy-D-Glucose (2-DG):

2-Deoxy-D-glucose is a glucose molecule and cannot undergo further glycolysis. It is labelled with tritium or carbon-14 has been a well-known ligand for laboratory research in animal models, where distribution is estimated by tissue-slicing followed by autoradiography, sometimes in tandem with either conventional or electron microscopy.

It is prohibitor of glucose transport and glycolysis, is known to inhibit the growth of neoplastic cells in vitro and in vivo. Globally, it has been studied in 218 clinical trials for the treatment of various cancers. However, based on mechanism, in-vitro-evidence as well efficacy seen in the interventional clinical studies in malignancies and genital herpes, by taking all this into consideration the sponsors believe that 2-DG could be developed for the specific treatment of patients with COVID-19 disease in conjunction with other anti-viral therapies.

2-DG was selected due to its in vitro inhibition potential (EC50 = 1.0 mM, EC90 = 3.7 mM; supernatant) towards SARS-CoV-2 from the studies conducted by Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi of the Defence Research and Development Organization (DRDO) at Centre for Cellular and Molecular Biology, Hyderabad. The Sponsor of this study, INMAS, DRDO, Ministry of Defence, Govt of India, was amenable for genesis of this hypothesis and testing of efficacy of 2-DG in opposition to SARS-CoV-2.
History of 2-DG

The National Institutes of Health, the University of Pennsylvania and Brookhaven National Laboratory of Japan carried out studies (1976) in the basic human neurosciences for mapping glucose metabolism in the living human brain (Ido et al, 1978; Reivich et al, 1979), resulting in synthesis of $^{18}$FDG i.e., 2-deoxy-2-$^{[18]}$F fluoro-D-glucose. $^{18}$FDG was modelled after carbon-14 labelled 2-deoxy-glucose (14C-2DG).

2-Deoxy-d-glucose (2-DG) is a glucose analogue, in which 2-hydroxyl group has been substituted with hydrogen. Bergmann, M., Schotte, H., Lechinsky, W., Ber 56, 1052 (1923) also gave us method to formulate 2-deoxy-D-glucose in low yield by mineral acid which is catalyzed addition of water to D-glucal. This preparation had many cons that it contains 9 steps which is time consuming. Another disadvantage in the process is resulting yield is very low about 2-5 % and the product is impure.

Properties of 2-DG

Additional names: D-arabino-2-desoxyhexose; 2-deoxyglucose; 2-DG

Molecular formula: C6H12O5

Molecular weight: 164.16

Percent composition: C 43.90%, H 7.37%, O 48.73%

Structure:

Preparation

Earlier many scientists have developed several methods to prepare 2-DG but due to its less yield and impurity their methods are not applied. After this the systemic steps are developed, they are as follows:

Conversion of D-glucose to glucose penta-acetate

20 to 25 wt% of D-glucose mixed with 60 to 65 wt % of acetic anhydride and 15 to 20 wt% of acetic acid are taken in a vessel. To this mixture, about 0.1 to 0.2 ml of H2SO4 is added which act as catalyst. There is an exothermic reaction and the acetic acid restrains the temperature of mixture to about 100°C and thus prevents the burning of glucose and splashing out of reactants. The reaction mixture is stirred under atmospheric pressure at room temperature for about 1 hour. A transparent solution of glucose penta-acetate in acetic acid solution is obtained.

Bromination of glucose pentaacetate to acetobromoglucose

In a separate vessel, tetralin 50-55% of the wt of glucose pentaacetate and bromine in the wt 85-90% of glucose pentaacetate are taken. This generates hydrogen bromide gas which is passed into the reaction mixture of step-1. The tetralin and bromine are in the ratio of 3:5. When the weight of reaction mixture increases about 35-40% of its weight, the passing of hydrogen bromide gas is discontinued. The vessel is kept in a cool place for carrying out the next reaction.

Reduction of acetobromoglucose to glucal triacetate

The acetobromoglucose procured by step-2 is reduced to glucal triacetate by reducing mixture comprising of four different constituents. The constituents of reducing mixture are activated zinc, sodium acetate, acetic acid and copper sulphate in aqueous medium at -1°C to 1°C. The quantities of these constituents as wt% of glucose pentaacetate are 25-30%, 50 to 55%, 50 to 55% and 2 to 3% respectively. The different constituents of the reducing mixture are in the simple ratio of 1:2:2:0.1.

After reduction, the mixture is filtered and diluted with water to about two times of its volume and is extracted with benzene or hexane. Benzene/hexane is removed under vacuum and viscous material left is diluted with 95% ethyl alcohol. After extraction and vacuum evaporation, the quantity of ethyl alcohol taken is about half of the volume of the product obtained. The yield of crystallised glucal triacetate thus obtained is in the order of higher than 70% of acetobromoglucose.

De-esterification of glucal triacetate to D-glucal

The glucal triacetate obtained is dissolved in dry methanol and add 1N-sodium methoxide. The quantity of dry methanol and IN-sodium methoxide is about four times and 20% of the weight of glucal triacetate. The mixture is then refluxed for 15 minutes. In a separate vessel, sodium carbonate and concentrated hydrochloric acid is poured over it through a pressure equalising funnel. The generated CO2 is passed into the reaction mixture till the mixture becomes neutral to slightly acidic. The methanol is removed under vacuum and the product obtained is D-glucal yield at this stage is about 30-35% of the glucal triacetate.

Hydration of D-glucal to 2-deoxy-D-glucose

The product obtained is diluted with distilled water and to this 1N H2SO4 is added. The quantity of water taken is about 20 times the weight of the product, whereas the quantity of 1N-sulphuric acid (H2SO4) taken is about 80% of
the weight of the product. For hydration the mixture is kept for 16-18 hours. Then excess acid is neutralised by barium carbonate. After filtration and evaporating the water under vacuum, the viscous liquid obtained is crystallised in dry isopropyl alcohol. After filtration, 2-DG is obtained have yield about 60% of the D-glucal.

**Purification**

The crude 2-DG obtained in step-5, is normally contaminated with barium sulphate. This impurity is removed by dissolving the crude 2-DG in water and filtered through membrane filter 0.45 microns. It is then passed through cation exchange resin like Dowex 50w. The quantity of resin taken is about 15 to 20% of the weight of crude 2-DG which is passed through anion exchange resin like Amberlite IRA-400OH. The quantity anion exchange resin is up to 30 to 35% of the weight of crude 2-DG. A shiny fluffy compound 2-DG is obtained which contains less than 2ppm of barium.14

**Synthesis**

**Role of 2-DG on SARS-CoV-2**

Covid-19 is mild to moderate respiratory illness which can be treated by drug therapy. As per the known information virus is inactive without a host, thus for further replication and survival they need machinery of the host. The source of energy is essential as they are unable to produce by itself. Virus depends on the energy produced in glycolysis cycle of the host body. The 2-DG itself a glucose molecule and act as a transporter but it correspondingly opposes the working of glycolysis.

It competitively inhibit the production of glucose-6-phosphate (G-6-P) from glucose at the phosphoglucoisomerase level in step 2 of glycolysis. Generally, in cells glucose hexokinase phosphorylates 2-deoxyglucose, trapping the product 2-deoxyglucose-6-phosphate (2-DG-P) intracellularly (except liver and kidney). Hence, labelled forms of 2-deoxyglucose serve as a good marker for tissue glucose uptake and hexokinase activity.13, 16

The virally infected cells have higher glucose uptake; thus 2-DG accumulates selectively more in such cells as it offers way to inhibiting viral infection. The same approach is applicable to treat the cancer as it inhibit the growth of tumor cell with tritium or carbon-14 ligand and also in inflammatory condition to reduce pain. They show their promising effect on ketogenic diet to act as anti-epileptic drug.17 Many authors suggested that 2-DG also works by positively increasing the expression of Brain-derived neurotrophic factor (BDNF), Basic fibroblast growth factor (FGF2), Arc (protein) (ARC) and Nerve growth factor (NGF).13, 18
Figure: Molecular structure of 2-deoxyglucose and its inhibition of glycolysis. (A) Molecular structure of glucose and 2-deoxyglucose. (B) Because of structural resemblance with glucose, 2-deoxyglucose enters the cell via gluts, leading to the interruption of glycolysis with decreased productions of ATP and lactate [6–8]. G: glucose. 2DG: 2-deoxyglucose.

CLINICAL TRIALS OF 2DG:

Dr. Reddy Laboratories and DRDO: Phase 2 clinical trial.

Table 4: Phase 2 clinical trials of 2-DG

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timepoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to ‘Clinical improvement’</td>
<td>Day 3, 7, 10, 14 and 28 (until patient reaches score of 4 or lower on 10 point ordinal scale for clinical status or discharge, whichever is earlier).</td>
</tr>
<tr>
<td>Change from baseline in mean viral load (determined by rRT-PCR on nasopharyngeal/oropharyngeal swab)</td>
<td>Days 3, 7, 10, 14 and 28</td>
</tr>
<tr>
<td>Percentage of patients showing negative conversion (of detectable SARS-CoV-2 viral RNA) on nasopharyngeal/oropharyngeal swab</td>
<td>Day 10 and Day 28</td>
</tr>
</tbody>
</table>

Mean/median time (no. of days) to negative conversion (of detectable SARS-CoV-2 viral RNA) on nasopharyngeal swab from day of first treatment intake

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timepoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary: outcomes</td>
<td></td>
</tr>
<tr>
<td>Secondary: outcomes</td>
<td></td>
</tr>
<tr>
<td>Percentage of patients who achieve the endpoint of Clinical improvement</td>
<td>Day 14 and Day 28</td>
</tr>
<tr>
<td>Mean/median time (no. of days) from start of study treatment to discharge from the isolation ward of the COVID management facility</td>
<td>Day 1 to Day 28</td>
</tr>
<tr>
<td>Mean change from baseline in patients clinical status on a 10-point ordinal scale (SOLIDARITY trial)</td>
<td>Days 3, 7, 14, 21 and 28 (or discharge, if discharge happens before)</td>
</tr>
<tr>
<td>Mean change from baseline in NEWS-2 score</td>
<td>Days 3, 7, 14, 21 and 28 (or discharge, if discharge happens before)</td>
</tr>
<tr>
<td>Percentage of patients requiring, until Day 28 of treatment:</td>
<td></td>
</tr>
<tr>
<td>a. Management in intensive care unit (ICU)</td>
<td>Day 28</td>
</tr>
<tr>
<td>b. Oxygen supplementation</td>
<td></td>
</tr>
<tr>
<td>c. Invasive mechanical ventilation</td>
<td></td>
</tr>
<tr>
<td>Mean/median time (no. of days) to a. Management in intensive care unit (ICU)</td>
<td>Day 28</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>b. Oxygen supplementation</strong></td>
<td>Day 28</td>
</tr>
<tr>
<td><strong>c. Invasive mechanical ventilation</strong></td>
<td>Day 14</td>
</tr>
</tbody>
</table>

**Mean/median time (no. of days) to**

- Management in intensive care unit (ICU)
- On Oxygen supplementation
- On Invasive mechanical ventilation

**Mean/median time to achieve symptom improvement of at least 30% in the COVID-19 symptoms sum score from baseline**

**Percentage of patients dying due to COVID-19 complication**

**Number (and percentage) of patients reporting treatment emergent adverse event (TEAEs) (by MedDRA system organ class and preferred term)**

**Changes of parameters at each assessment during the study/follow-up period, compared to baseline for:**
- **Vital signs:** body temperature, heart rate, respiratory rate, systolic/diastolic blood pressure and oxygen saturation.
- **Clinical laboratory assessments:** hematology, serum chemistry, urinanalysis.
- **12-lead ECG:** Changes in heart rate, PR, QRS, QT and QTcB intervals.

**Target sample size:** Total Sample Size=40

**Sample Size from India=40**

**Final Enrolment numbers achieved (Total) =110**

**Final Enrolment numbers achieved (India) =110**

**Phase of trial:** Phase 2

**Date of first:** 15/06/2020

After 2DG successful results in phase 2, DCGI further permitted the Phase-III clinical trials in November 2020, which is carried out on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in various states like Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu.

The detailed data of phase-III clinical trial was presented to DCGI. In 2-DG arm, greater proportion of patients improved symptomatically, which gradually indicates an early relief from oxygen therapy/dependence. According to the clinical trial registry data, the estimated duration of these trials are eight months and should therefore continue till August 2021.

**Figure 5:** Cyto-pathic effect of 2-DG and inhibiting SARS-CoV-2.

The study design was based on randomized, parallel group and active group trials.

Male, female and transgender patients of age >18 and <65 years are taken for study. Patients testing positive for SARS-CoV-2 by rRTPCR on nasopharyngeal or oropharyngeal swab.
Note: A re-treated patient may be enrolled if he/she meet all of the following criteria:

1. Documented re-conversion on nasopharyngeal or oropharyngeal swab from negative to positive for SARS-CoV-2 or nasopharyngeal or oropharyngeal swab continues to be positive for SARS-CoV-2 after previous treatment.
2. Clinical symptoms associated with covid-19 (fever, cough, difficulty in breathing, fatigue, body ache, headache, diarrhea, nasal congestion) have either re-appeared after previous treatment or continued to be present without improvement or are aggravated.

Phase 2a was conducted in six hospitals and Phase 2b (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-2 trial was conducted on 110 patients. Regulatory clearance status from DCGI- Approved/obtained.

Dose of 2-DG in intervention and comparative study

<table>
<thead>
<tr>
<th>Type</th>
<th>Name</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>2-deoxyglucose oral powder</td>
<td>45mg/kg in morning+ 18mg/kg in evening but no longer than discharge or day28.</td>
</tr>
<tr>
<td>Comparator agent</td>
<td>Standard of care</td>
<td>Upto day 28 discharge but not more than day 28.</td>
</tr>
</tbody>
</table>

Adjuvant Therapy of 2-Deoxyglucose

The antiviral effects of 2-DG, which is attributed to the direct interaction of 2-DG with the virus (preventing viral entry into host cells) and compromising the high energy demand by glycolysis inhibition. In silico studies suggest that the structure of 2-DG fits into protease 3Clpro also as NSP15 endoribonuclease, leading to the inhibition of SARS-CoV-2 receptors binding to the host cells, which needs validation. Moreover, 2-DG has also been shown to exert anti-inflammatory effects. Preliminary in vitro studies have shown the potential of 2-DG in reducing the viral load in host cells, supported these polypharmacological effects of 2-DG (glycolysis inhibition, anti-inflammatory action, and interaction with viral proteins, 2-DG has been suggested as a therapeutic for the management of COVID-19 patients. Further, the facility of 2-DG in restoring CD/CD8 ratio, enhancing NK cells and IFNy levels including improved antigen presenting ability of macrophages reported by us earlier suggest that 2-DG also can improve the immune status compromised by COVID-19. However, the dose of 2-DG required and daily administration needed may cause concern regarding non-target effects within the type of CNS disturbances and cardio-respiratory disturbances. Additionally to 2-DG, baricitinib, remdesivir are often utilized together in paediatric patients and two years aged too.

Various Pharma Industries and Laboratories Involved In Preparation of 2-DG

2-DG was chosen supported it’s in vitro inhibition potential (EC50 = 1.0 mm, EC90 = 3.7 mm; supernatant) towards SARS-CoV-2 from the studies conducted by Institute of drugs & Allied Sciences (INMAS), Delhi of the Defence Research and Development Organization (DRDO) at Centre for Cellular and biology, Hyderabad. The Sponsor of this study, INMAS, DRDO, Ministry of Defence, Govt of India, was responsible for genesis of this hypothesis and testing of efficacy of 2-DG against SARS-CoV2. These effective concentrations are within the range which can be achieved in human plasma upon oral dosing of 63 mg/kg/day.

The Drug Controller General of India (DCGI) had announced on 1May 2021 emergency approval for using 2DG on COVID-19 patients. the tactic has been established at batch scale (100g) and pilot plant scale (500g). The patents are filled by DRDO during this regard. For the assembly of drug by other Indian Pharmaceutical industries DRDO have offered Transfer of Technology (ToT). The Indian Pharmaceutical industries shall fulfil the next criteria/requirements proposed by DRDO:

1. Drug License to manufacture Active Pharmaceutical ingredient (API) from Drug Licensing Authorities.
2. API production capability.
3. WHO GMP (Good Manufacturing Practices) certification.
4. Drug manufacturing facility consisting of chemical operation like acetylation, bromination, reductions etc. over wide temperature rage (-5 ˚C to 100 ˚C) and unit operations like vacuum filtration, vacuum distillation, extraction and crystallisation.
5. Capacity to take in the technology and have capacity to provide the API with approximately 2000 kg per month and convey the drug within the market within a shortest possible time.
6. Fulfilment of all regulatory requirements for manufacturing, QA/ QC etc. for the API.

7. Not under any ban by Govt of India/ Any state Govt/ UT or any Govt Agency.

8. Not be under insolvency resolution.

9. In-house R&D facilities for API.  

List of Indian pharmaceutical industries and laboratories issued licence to manufacture and market 2DG:

1) Dr. Reddy Laboratories + NIMAS
2) Laurus Labs
3) Shilpa Medicare
4) BDR Pharmaceuticals
5) Lee Pharma + City-based Indian Institute of Chemical Technology (IICT) - CSIR
6) Hyderabad-based MSN Labs (brand name MSN 2D)
7) PI Industries Limited + IICT- CSIR
8) Anthem Biosciences + IICT – CSIR

The utmost selling price of the drug is capped at ₹ 990, with a reduced rate offered to government institutions. It’s currently manufacturing in Dr. Reddy’s laboratories with DRDO. The participants who got 2-DG had better ‘symptom improvement’ and spent less time receiving supplemental oxygen. Some adverse effects are shown by 2-DG are reversible hyperglycaemia, gastrointestinal bleeding, headache.

CONCLUSION

➢ Many patients of all age group in several states are administered this drug shows promising results to recover readily from SARS-CoV-2 said by the govt. hence it’s sanctioned for treatment for this deadly disease.

➢ Consistent with the studies administered on mechanism and therapeutic efficacy of 2-DG it has been predicted to oppose this virus.

➢ Many industries are now involved in production of 2-DG with license.

➢ Combinational approach with specified antiviral shows synergistic effect i.e. it increases its therapeutic window.

➢ From the study, the phase 2 clinical trials of 2-DG are successfully administered, and it's approved by DRDO for emergency situation in mild to moderate condition of disease is concluded.

REFERENCES


5. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research


Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any question relates to this article, please reach us at: editor@globalresearchonline.net
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com